Fibroblast Activation Protein (FAP) Targeted Therapy: a Competitor Analysis

This competitive intelligence report about FAP-Targeted Therapy provides a competitor evaluation in the field of product candidates in research and development targeting Fibroblast Activation Protein (FAP). This report will be prepared on demand within one working day upon order placement. The report lists FAP-targeted R&D programs by R&D phase in a tabular format and describes in brief the profile of FAP-targeted therapies by drug modality. The report will be provided in pdf format and sent by e-mail to the customer.

As an example of this category of on demand reports please see our free sample report of “Pipeline of 5T4-Targeted Immunotherapies”.

Fibroblast activation protein (FAP) is selectively expressed in reactive stromal fibroblasts of epithelial cancers, granulation tissue of healing wounds, and malignant cells of bone and soft tissue sarcomas. This protein is thought to be involved in the control of fibroblast growth or epithelial-mesenchymal interactions during development, tissue repair, and epithelial carcinogenesis.

FAP is expressed on cancer associated fibroblasts (CAFs), a particular cell type found in the tumour microenvironment. CAFs are found in a broad range of cancers (e.g. breast, colorectal, pancreatic, lung, brain and ovarian cancers), but only minimally in normal tissue, making FAP a promising pan-cancer target for both imaging and treatment of cancers. CAFs form part of the environment surrounding the cancer cells, and they can promote cancer growth and the spread of the tumor throughout the body. Targeting the tumor stroma is an alternative way to treat cancer whereby the architecture of the tumor mass is targeted rather than the tumur cells directly.

Targeting of FAP is well suited for tumor stroma delivery of effector moieties such as radioactive or cytotoxic payloads, stimulatory agonists, redirected cytotoxic T-cells, and cytokines/chemokines.